AMB-053 is under clinical development by AmMax Bio and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMB-053’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMB-053 is under development for the treatment of idiopathic pulmonary fibrosis (IPF). The drug candidate is a human monoclonal antibody which acts by targeting macrophage colony stimulating factor 1 receptor (CSF1R).
AmMax Bio overview
AmMax Bio, is a biotechnology company that focused on clinical development of oncology therapeutics, novel next generation antibody drug conjugate, treatment of tenosynovial giant cell tumors and other biotech services. The company is headquartered in Redwood City, California, the US.
For a complete picture of AMB-053’s drug-specific PTSR and LoA scores, buy the report here.